Dr. Corina Andresen

Dr. Corina Andresen has a diverse and extensive work experience in various roles within the pharmaceutical and biotechnology industry. Dr. Corina most recently served as the Vice President of Clinical Development for Oncology at SonALAsense, where they led the clinical trials for their sonodynamic therapy (SDT) using a combination of a drug and MR-guided focused ultrasound.

Prior to SonALAsense, Dr. Andresen was the Vice President of Clinical Development at Accutar Biotechnology, where they played a crucial role in the company's clinical development efforts.

In 2019, they held the position of Executive Director of Clinical Development at QED, contributing to their clinical development initiatives.

Before QED, Dr. Andresen worked as the Lead Clinical Development for Immune Oncology at Nektar Therapeutics, focusing on the development of therapies in this area.

Dr. Corina also served as the Executive Medical Director at Iovance Biotherapeutics and worked as a Senior Medical Director at Pfizer. At Pfizer, they were involved in the registration Phase 3 study for enzalutamide, which led to its approval in chemo-naïve patients with castration-resistant prostate cancer (cRPC).

Dr. Andresen has prior experience at Medivation Inc., Eisai, Cerimon Pharmaceuticals, and Exelixis, where they held positions of increasing responsibility and contributed to various clinical development projects.

Overall, Dr. Corina Andresen has a strong background in clinical development and a proven track record of success in the pharmaceutical and biotechnology industry.

Dr. Corina Andresen pursued their education at the School of Medicine, where they completed the Pediatrics and Anesthesia Residency Program in Germany. Dr. Corina obtained a Doctor in Medicine (MD) degree from this institution, but the specific years of their education are not mentioned.